MDS Flashcards

1
Q

What are some low risk MDS genetic defining events?

A

MDS w/5q deletion
MDS w/SF3B1 mutation
These are both low blast/low risk MDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is a high risk MDS genetic defining event?

A

MDS with biallelic TP53 mutations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some high risk cytogenetic abnormalities with MDS?

A

Think anything with chromosome 3 is bad. Inv3, del3q, t(3q), del7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some good risk MDS cytogenetic abnormalities? If you don’t remember all of these it’s okay, more so important to know the high risk ones.

A

del 5q, del 11q, del 12p, del 20q

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What MDS mutation is associated with a good prognosis and is the only one for this?

A

SF3B1 mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When treating a MDS patient who has anemia with a ESA agent, what level predicts for response?

A

If they have a level of 200 or less they most likely will get a response, otherwise it likely won’t work.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Luspatercept approved for in MDS?

A

It is approved for the treatment of very low risk to intermediate risk MDS w/ringed sideroblasts that is refractory to a ESA or will not respond to ESA due to high EPO. Also approved for MDS/MPN-RS-T.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When using Luspatercept in MDS what signaling is affected and how?

A

It decreases SMAD2 and SMAD3 signaling (normally when this pathway is active it inhibits RBC maturation).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the approval for Lenalidomide for MDS?

A

Patients with low risk to intermediate risk disease with 5q del who are transfusion dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the mechanism of action of Lenalidomide in MDS?

A

It modulates E3 ubiqutin ligase cereblon activity, this in turn alters the degradation of casein kinase 1 which increases Wnt/B-catenin signaling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the only medication that is associated with a survival benefit in high risk MDS besides transplant?

A

Azacitidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Remember to yourself, what defines high risk MDS, in terms of blast count, platelet, and Hgb?

A

Marrow Blast Count>10%
Hgb less than 8
Platelet Count less than 50K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the treatment options for high risk MDS who are not eligible for transplant?

A

Azacitidine, Decitabine, Oral decitabine in combination with cedazuridine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

All high risk patients with MDS should be pushed for what?

A

Transplant unless there are contraindications.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly